Deepti Dhall, MD

Email: Deepti.Dhall@cshs.org
Phone: 310-423-6623

Grant Medical College, Mumbai, India; MD
Residency in Anatomic and Clinical Pathology, Robert Wood Johnson University Hospital, New Brunswick, NJ
Fellowship in Oncologic Surgical Pathology and Gastrointestinal Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY

Recognized for outstanding contributions to resident education, Cedars-Sinai Medical Center, Department of Pathology
Invited speaker, US and Canadian Academy of Pathology

Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D. Value of Islet 1 and PAX8 in Identifying Metastatic Neuroendocrine Tumors of Pancreatic Origin. Modern Pathol 2012; 25:893-901.
Dhall D, Mertens R, Parakh R, Dhall G, Ines D, Chung F, Kim A, Li M, Colqhoun S, Mirocha J, Wang HL, Wolin E. Ki-67 proliferative index predicts progression free survival in ileal well-differentiated neuroendocrine tumors. Hum Pathol. 2012;43:489-95.
Short S, Stojadinovic A, Nissan A, Wainberg Z, Dhall D, Yao K, and Bilchik A. Adjuvant treatment of early colon cancer with micrometastases: results of two multicenter prospective trials and national survey. J Surg Oncol. 2012;106(2):119-22
Levy M, Trivedi A, Zhang J, Miles L, Mattis AN, Kim GE, Lassman C, Anders RA, Misdraji J, Yerian LM, Xu H, Dhall D, Wang HL. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol. 2012;43(5):695-701.
Yu R, Dhall D, Nissen NN, Ren SG. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One. 2011;6(8):e23397.

Click here for a list of peer-reviewed publications by Deepti Dhall, MD.